COVAX has an agreement to access to two billion doses of promising vaccine to the candidates. Negotiations continue to extend further doses to be secured through existing R&D agreements by co-lead the Coalition for Epidemic Preparedness Innovations (CEPI), and through evaluations of the latest products with promising results and contributions from several donors.

Based on this, COVAX anticipates having the ability to supply participating economies the doses of safe and effective vaccines – enough to guard health care and other frontline workers also as some high-risk individuals – beginning in Q1 2021. The aim is to guard a minimum of 20% of every participating population by the top of the year – unless a participant has requested a lower percentage of doses. Around 1.3 billion of those doses are going to be made available to the 92 eligible economies by the top of 2021.

To meet its goal of securing two billion safe and effective vaccines in 2021, COVAX has built a various portfolio of vaccine candidates which mitigates the danger of a product bombing creation, advancement or administrative cycles, and guarantees accessibility of items reasonable for various contexts. This work will continue at pace to enable further supply of vaccines suitable to be used across a good range of populations and settings in 2021 and beyond.

Continuous advancement in antibody improvement has been unprecedented and plainly and we are presently gathering the instruments that we’d prefer to bring the intense period of the pandemic to an end, we cannot afford to slow down our efforts considering the speed at which this pandemic continues to wreak havoc. Newer COVID-19 variant puts us into sharp focus situation and the necessity to be one step forward before the virus by continuing to take a position in vaccine R&D for next-generation vaccine candidates and to be ready for changes in existing vaccines as per strain to make sure we’ve all the useful resources to satisfy the requirements of all populations for the future.